drugset / Trial / NCT03046446

Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee

NCT03046446

Phase 3 Completed 208 enrolled Pacira Pharmaceuticals, Inc
NaSingle-groupOpen-labelTreatment

Summary

This is an Open-label Study to Assess the Safety of Repeat Dose of FX006 Administered to Patients with Osteoarthritis (OA) of the Knee

Timeline

Start
2017-02-20
Primary completion
2018-07-19
Completion
2018-07-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Acetonide Other / unclassified 32 mg Other

Indications